# US 2016/0237057 A1 · Diarylalkylamine rev-erb antagonists and their use as medicaments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0237057 A1
- Document ID: US20160237057A1
- Status: Published application
- Kind: A1
- Application number: 15/027,951
- Filed: 2014-10-09
- Published: 2016-08-18
- Earliest claimed: 2013-10-09
- Assignees: Fondazione Istituto Italiano Di Tecnologia
- Applicants: Fondazione Istituto Italiano Di Tecnologia
- Inventors: Benedetto Grimaldi; Esther Torrente; Rita Scarpelli; Giovanni Bottegoni; Tiziano Bandiera; Marina Veronesi
- Web page: https://patentgrep.com/patent/US20160237057A1

## CPC

- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/4453: only substituted in position 1, e.g. propipocaine, diperodon
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 211/06: having no double bonds between ring members or between ring members and non-ring members
- C07D 211/58: attached in position 4
- C07D 241/38: with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D 295/04: with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D 295/08: substituted by singly bound oxygen or sulfur atoms
- C07D 295/16: acylated on ring nitrogen atoms
- C07D 295/185: from aliphatic carboxylic acids
- C07D 309/14: Nitrogen atoms not forming part of a nitro radical
- C07D 333/08: Hydrogen atoms or radicals containing only hydrogen and carbon atoms
- C07D 333/20: by nitrogen atoms (nitro, nitroso radicals C07D333/12)
- C07D 471/08: Bridged systems
- C07D 487/08: Bridged systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses as anti-proliferative and pro-apoptotic agents for cancer therapy.

## Claims

### Claim 1

A compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein Ar and Ar′ are independently selected from the group consisting of a 5- to 10-membered aromatic and heteroaromatic single or fused rings comprising up to 3 heteroatoms selected from N, O and S;
R is selected from the group consisting of hydrogen, a linear or branched unsubstituted or substituted C1-6 alkyl and an unsubstituted or substituted aryl C1-6 alkyl;
R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, linear or branched, unsubstituted or substituted C1-6 alkyl, C1-6alkoxy, hydroxy C1-6 alkyl, OH, CN, fluoro C1-6 alkyl and fluoro C1-6 alkoxy; R1, R2, R3 and R4 can be attached to any position of Ar and Ar′ group, respectively;
Y is selected from the group consisting of N and CH;
X is selected from the group consisting of CH and N;
R5 and R6 are independently selected from the group consisting of H, halogen, unsubstituted or substituted linear or branched C1-6 alkyl, ═O, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted arylCO, unsubstituted or substituted aryl C1-6 alkylCO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9, and R10 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl; R5 and R6 can be attached to any carbon atom of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring; and
R11 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, aryl and aryl C1-6 alkyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring, saturated or unsaturated, and containing up to two nitrogen atoms;
q and p are, independently, 0 or an integer from 1 to 2 with the proviso that when both Y and X are N, neither q and p are 0;
R12 and R13 are independently selected from the group consisting of H, F, C1-6 alkyl, C1-6 alkyl-OH, ═O, OH, COOH, CO2Me, CONH2, CONHMe and CONMe2 and can be attached to any position of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O, S and NR14, wherein R14 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, unsubstituted or substituted arylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and linear or branched C1-6 alkyl;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 3 with the proviso that when W is bond, n is not 0;
provided that the compound of Formula (I) is not:
4-[[[1-(4-methoxyphenyl)cyclopentyl]amino]methyl]-2-[(4-methyl-1-piperazinyl)methyl]-phenol;
4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methyl-1-piperazinyl)methyl]-phenol or
4-[[[1-(2-methoxyphenyl)cyclopentyl]amino]methyl]-2-[(4-methyl-1-piperazinyl)methyl]-phenol.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein:
Ar and Ar′ are, independently, selected from benzene, pyridine, naphthalene and thiophene rings;
R is selected from the group consisting of H, CH3 and unsubstituted or substituted phenylCH2;
R1, R2, R3 and R4 are independently selected from the group consisting of H, F, Cl, CH3, OH, OCH3, CH2OH, CF3, CHF2, CH2F, CF2CF3, OCF3, OCF2CF3 and CN;
R5 and R6 are independently selected from the group consisting of H, F, CH3, ═O, unsubstituted or substituted phenyl, unsubstituted or substituted pyridyl, unsubstituted or substituted phenylCH2, CH2OH, CH3CO, unsubstituted or substituted phenylCO, unsubstituted or substituted phenylCH2CO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9, and R10 are independently selected from the group consisting of H and CH3;
R11 is selected from the group consisting of H, CH3, Et, i-Pr, phenylC1-6 alkyl, CH3CO and phenyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form a ring and thus the moiety:
has a meaning selected from the group consisting of:
p and q are, independently, 0 or 1;
R12 and R13 are independently selected from the group consisting of H, F, CH3, CH2OH, OH and ═O, and are connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O and NR14, wherein R14 is H, CH3, COCH3, unsubstituted or substituted phenyl, unsubstituted or substituted phenyl CH2, unsubstituted or substituted phenylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and CH3;
m is an integer from 1 to 3, and n is an integer from 1 to 2.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein W is selected from the group consisting of a bond, O, NH, NCH3, NCOCH3 and NCH2phenyl.

### Claim 4 (depends on 1)

The compound according to claim 1, having the Formula (I′):
wherein:
Ar and Ar′ are, independently, selected from benzene, pyridine, naphthalene and thiophene rings;
R is selected from the group consisting of H and CH3;
R1 and R3 are independently selected from the group consisting of H, F, CH3, OCH3, OH, CF3 and CN;
R2 and R4 are, independently, H or F;
p and q are equal to 1, m is an integer from 1 to 2, n is an integer from 1 to 2;
R12 and R13 are independently selected from the group consisting of H, F, CH3, CH2OH, ═O and OH, and they are connected to the same carbon atom or to different carbon atoms of the ring;
W is a bond, O, NH, NCH3, NCOCH3 or NCH2phenyl;
Y is selected from the group consisting of N and CH;
R5 and R6 are independently selected from the group consisting of H, F, CH3, ═O, phenyl, pyridyl, phenylCH2, CH2OH, CH3CO and COOH;
R11 is selected from the group consisting of H, CH3, Et, i-Pr, phenylCH2, CH3CO, phenyl and phenyl(CH2)2;
or R5 and R6, R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring wherein the moiety:
has a meaning selected from the group consisting of:

### Claim 5 (depends on 4)

The compound according to claim 4 wherein R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring wherein the moiety:
has a meaning selected from the group consisting of:

### Claim 6 (depends on 1)

The compound according to claim 1, having the Formula (I″):
wherein Ar and Ar′ are, independently, selected from benzene, pyridine, naphthalene and thiophene rings;
R is H and CH3;
R1 and R3 are independently selected from the group consisting of H, F, CH3, OCH3, OH and CF3;
R2 and R4 are both H;
p and q are equal to 1, m is an integer from 1 to 2, n is an integer from 1 to 2;
R12 and R13 are independently selected from the group consisting of H, F, CH3, CH2OH, ═O and OH, or R12 and R13 are connected to the same carbon atom and have both the same meaning selected from F and CH3;
W is a bond, O, NH, NCH3, NCOCH3 or NCH2phenyl;
Y is N or CH;
R5 and R6 are independently selected from the group consisting of H, F, CH3, ═O, phenyl, pyridyl, phenylCH2, CH2OH, CH3CO and COOH;
R11 is selected from the group consisting of H, CH3, Et, i-Pr, phenylCH2, CH3CO and phenyl;
or R5 and R6, R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring wherein the moiety:
has a meaning selected from the group consisting of:

### Claim 7 (depends on 6)

The compound according to claim 6 wherein Ar and Ar′ are benzene rings.

### Claim 8 (depends on 6)

The compound according to claim 6 wherein R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring wherein the moiety:
has a meaning selected from the group consisting of:

### Claim 9 (depends on 1)

The compound according to claim 1, selected from the group consisting of:
4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-(1-piperidylmethyl)phenol dihydrochloride;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
1-(2-fluorophenyl)-N-[[3-[(4-methylpiperazin-1-yl)methyl]phenyl]methyl]cyclopentanamine trihydrochloride;
1-(2-fluorophenyl)-N-[[4-methoxy-3-[(4-methylpiperazin-1-yl)methyl]phenyl]methyl]cyclopentanamine trihydrochloride;
4-[[[1-(2-fluorophenyl)cyclopentyl]-methyl-amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
2-[(4-methylpiperazin-1-yl)methyl]-4-[[(1-phenylcyclopentyl)amino]methyl]phenol trihydrochloride;
1-[4-[[5-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-hydroxyphenyl]methyl]piperazin-1-yl]ethanone dihydrochloride;
4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-phenylpiperazin-1-yl)methyl]phenol trihydrochloride;
2-[(4-ethylpiperazin-1-yl)methyl]-4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]phenol trihydrochloride;
4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-(piperazin-1-ylmethyl) phenol;
2-[(4-benzylpiperazin-1-yl)methyl]-4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]phenol trihydrochloride;
4-[[[1-(2-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-isopropylpiperazin-1-yl)methyl]phenol trihydrochloride;
4-[[[1-(2-fluorophenyl)tetrahydropyran-4-yl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
4-(2-fluorophenyl)-4-[[4-hydroxy-3-[(4-methylpiperazin-1-yl)methyl]phenyl]methylamino]cyclohexanone trihydrochloride;
4-[[[4,4-difluoro-1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(4-methyl-piperazin-1-yl)methyl]phenol trihydrochloride;
1-(2-fluorophenyl)-N-[[3-[(1-methyl-4-piperidyl)methyl]phenyl]methyl]cyclopentanamine dihydrochloride;
1-(2-fluorophenyl)-N-methyl-N-[[3-[(1-methyl-4-piperidyl)methyl]phenyl]methyl]cyclopentanamine dihydrochloride;
4-[[[1-benzyl-4-(2-fluorophenyl)-4-piperidyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol tetrahydrochloride;
4-[[[1-(2,4-difluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
4-[[[1-(3-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
4-[[[1-(4-fluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol trihydrochloride;
2-[(4-methylpiperazin-1-yl)methyl]-4-[[[1-(3-thienyl)cyclopentyl]amino]methyl]phenol trihydrochloride;
2-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-6-[(4-methylpiperazin-1-yl)methyl]phenol;
1-(2-fluorophenyl)-N-[[2-[(4-methylpiperazin-1-yl)methyl]-4-pyridyl]methyl]cyclohexanamine;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(5-methyl-2,5-diazabicyclo[2.2.2]octan-2-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(4-methyl-2,3-dihydroquinoxalin-1-yl)methyl]phenol;
2-(1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazin-2-ylmethyl)-4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]phenol;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(9-methyl-3,9-diazabicyclo[3.3.1]nonan-3-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-[(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl]phenol;
4-[[[1-(3,5-difluorophenyl)cyclopentyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(3-fluoro-2-naphthyl)cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-3-[(4-methylpiperazin-1-yl)methyl]phenol;
2-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-4-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-hydroxyphenyl)cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)-4-methyl-cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)-4-(hydroxymethyl)cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)-4-hydroxy-cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
1-(2-fluorophenyl)-N-[[3-[(1-phenethyl-4-piperidyl)methyl]phenyl]methyl]cyclohexanamine;
4-[[[1-(2-fluorophenyl)-4-hydroxy-4-methyl-cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[[1-(2-fluorophenyl)-4,4-dimethyl-cyclohexyl]amino]methyl]-2-[(4-methylpiperazin-1-yl)methyl]phenol;
4-[[5-[[[1-(2-fluorophenyl)cyclohexyl]amino]methyl]-2-hydroxy-phenyl]methyl]-1-methyl-piperidine-2-carboxylic acid;
1-(2-fluorophenyl)-N-[[3-[(1-methyl-4-piperidyl)methyl]phenyl]methyl]cyclohexanamine;
1-(3-fluorophenyl)-N-[[3-[(1-methyl-4-piperidyl)methyl]phenyl]methyl]cyclopentanamine;
N-[[3-[(1-benzyl-4-piperidyl)methyl]phenyl]methyl]-1-(2-fluorophenyl)cyclohexanamine;
1-(2-fluorophenyl)-N-[[3-[(1-methyl-3,4-dihydro-2H-quinolin-4-yl)methyl]phenyl]methyl]cyclohexanamine;
N-[[3-(cyclohexylmethyl)phenyl]methyl]-1-(2-fluorophenyl)cyclohexanamine; and
1-(2-fluorophenyl)-N-[[3-[(4-methylcyclohexyl)methyl]phenyl]methyl]cyclohexanamine.

### Claim 10

A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein Ar and Ar′ are independently selected from the group consisting of a 5- to 10-membered aromatic or heteroaromatic single or fused rings comprising up to 3 heteroatoms selected from N, O and S;
R is selected from the group consisting of hydrogen, a linear or branched unsubstituted or substituted C1-6 alkyl and an unsubstituted or substituted aryl C1-6 alkyl;
R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, linear or branched, unsubstituted or substituted C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, fluoro C1-6 alkyl and fluoro C1-6 alkoxy; R1, R2, R3 and R4 can be attached to any position of Ar and Ar′ group, respectively;
Y is selected from the group consisting of N and CH;
X is selected from the group consisting of CH and N;
R5 and R6 are independently selected from the group consisting of H, halogen, unsubstituted or substituted linear or branched C1-6 alkyl, ═O, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted arylCO, unsubstituted or substituted aryl C1-6 alkylCO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl; R5 and R6 can be attached to any carbon atom of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring; and
R11 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6alkylCO, aryl and aryl C1-6 alkyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring, saturated or unsaturated, and containing up to two nitrogen atoms;
q and p are, independently, 0 or an integer from 1 to 2 with the proviso that when both Y and X are N, neither q and p are 0;
R12 and R13 are independently selected from the group consisting of H, F, C1-6 alkyl, C1-6 alkyl-OH, ═O, OH, COOH, CO2Me, CONH2, CONHMe and CONMe2 and can be attached to any position of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O, S and NR14, wherein R14 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, unsubstituted or substituted arylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and linear or branched C1-6 alkyl;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 3 with the proviso that when W is bond, n is not 0;
and a pharmaceutically acceptable carrier, stabilizer, diluent or excipient thereof.

### Claim 11

A method of modulating REV-ERBs activity in a cell, wherein the method comprises contacting the cell with a modulating amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein Ar and Ar′ are independently selected from the group consisting of a 5- to 10-membered aromatic and heteroaromatic single or fused rings comprising up to 3 heteroatoms selected from N, O and S;
R is selected from the group consisting of hydrogen, a linear or branched unsubstituted or substituted C1-6 alkyl and an unsubstituted or substituted aryl C1-6 alkyl;
R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, linear or branched, unsubstituted or substituted C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, fluoro C1-6 alkyl and fluoro C1-6 alkoxy; R1, R2, R3 and R4 can be attached to any position of Ar and Ar′ group, respectively;
Y is selected from the group consisting of N and CH;
X is selected from the group consisting of CH and N;
R5 and R6 are independently selected from the group consisting of H, halogen, unsubstituted or substituted linear or branched C1-6 alkyl, ═O, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted arylCO, unsubstituted or substituted aryl C1-6 alkylCO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl; R5 and R6 can be attached to any carbon atom of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring; and
R11 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, aryl and aryl C1-6 alkyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring, saturated or unsaturated, and containing up to two nitrogen atoms;
q and p are, independently, 0 or an integer from 1 to 2 with the proviso that when both Y and X are N, neither q and p are 0;
R12 and R13 are independently selected from the group consisting of H, F, C1-6 alkyl, C1-6 alkyl-OH, ═O, OH, COOH, CO2Me, CONH2, CONHMe and CONMe2 and can be attached to any position of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O, S and NR14, wherein R14 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, unsubstituted or substituted arylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and linear or branched C1-6 alkyl;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 3 with the proviso that when W is bond, n is not 0.

### Claim 12 (depends on 10)

A method of treating a disease or pathology associated with REV-ERBs activity in a mammal, wherein the method comprises administering to the mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein Ar and Ar′ are independently selected from the group consisting of a 5- to 10-membered aromatic and heteroaromatic single or fused rings comprising up to 3 heteroatoms selected from N, O and S;
R is selected from the group consisting of hydrogen, a linear or branched unsubstituted or substituted C1-6 alkyl and an unsubstituted or substituted aryl C1-6 alkyl;
R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, linear or branched, unsubstituted or substituted C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, fluoro C1-6 alkyl and fluoro C1-6 alkoxy; R1, R2, R3 and R4 can be attached to any position of Ar and Ar′ group, respectively;
Y is selected from the group consisting of N and CH;
X is selected from the group consisting of CH and N;
R5 and R6 are independently selected from the group consisting of H, halogen, unsubstituted or substituted linear or branched C1-6 alkyl, ═O, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted arylCO, unsubstituted or substituted aryl C1-6 alkylCO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl; R5 and R6 can be attached to any carbon atom of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring; and
R11 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, aryl and aryl C1-6 alkyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring, saturated or unsaturated, and containing up to two nitrogen atoms;
q and p are, independently, 0 or an integer from 1 to 2 with the proviso that when both Y and X are N, neither q and p are 0,
R12 and R13 are independently selected from the group consisting of H, F, C1-6 alkyl, C1-6 alkyl-OH, ═O, OH, COOH, CO2Me, CONH2, CONHMe and CONMe2 and can be attached to any position of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O, S and NR14, wherein R14 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, unsubstituted or substituted arylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and linear or branched C1-6 alkyl;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 3 with the proviso that when W is bond, n is not 0,
or a pharmaceutical composition according to claim 10.

### Claim 13 (depends on 10)

A method of treating cancer associated with REV-ERBs activity in a mammal, wherein the method comprises administering to the mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof:
wherein Ar and Ar′ are independently selected from the group consisting of a 5- to 10-membered aromatic and heteroaromatic single or fused rings comprising up to 3 heteroatoms selected from N, O and S;
R is selected from the group consisting of hydrogen, a linear or branched unsubstituted or substituted C1-6 alkyl and an unsubstituted or substituted aryl C1-6 alkyl;
R1, R2, R3 and R4 are independently selected from the group consisting of H, halogen, linear or branched, unsubstituted or substituted C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, fluoro C1-6 alkyl and fluoro C1-6 alkoxy; R1, R2, R3 and R4 can be attached to any position of Ar and Ar′ group, respectively;
Y is selected from the group consisting of N and CH;
X is selected from the group consisting of CH and N;
R5 and R6 are independently selected from the group consisting of H, halogen, unsubstituted or substituted linear or branched C1-6alkyl, ═O, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted arylCO, unsubstituted or substituted aryl C1-6 alkylCO, COOR7, CONR8R9 and SO2R10 wherein R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl; R5 and R6 can be attached to any carbon atom of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring; and
R11 is selected from the group consisting of —H, linear or branched C1-6 alkyl, C1-6 alkylCO, aryl and aryl C1-6 alkyl;
or R5 and R6, or R5 and R11 or R6 and R11 are linked together to form an unsubstituted or substituted 4- to 10-membered ring, saturated or unsaturated, and containing up to two nitrogen atoms;
q and p are, independently, 0 or an integer from 1 to 2 with the proviso that when both Y and X are N, neither q and p are 0;
R12 and R13 are independently selected from the group consisting of H, F, C1-6 alkyl, C1-6 alkyl-OH, ═O, OH, COOH, CO2Me, CONH2, CONHMe and CONMe2 and can be attached to any position of the ring to which they are connected and they may be connected to the same carbon atom or to different carbon atoms of the ring;
W is selected from the group consisting of a bond and a heteroatom selected from the group consisting of O, S and NR14, wherein R14 is selected from the group consisting of H, linear or branched C1-6 alkyl, C1-6 alkylCO, unsubstituted or substituted aryl, unsubstituted or substituted aryl C1-6 alkyl, unsubstituted or substituted arylCO, SO2R15, CONR16R17 and COOR18, wherein R15, R16, R17 and R18 are independently selected from the group consisting of H and linear or branched C1-6 alkyl;
m is an integer from 1 to 3, n is 0 or an integer from 1 to 3 with the proviso that when W is bond, n is not 0;
or a pharmaceutical composition according to claim 10.

### Claim 14 (depends on 13)

The method according to claim 13 wherein the cancer is Erb-B2 positive cancer.

### Claim 15 (depends on 13)

The method according to claim 13 wherein the cancer is selected from the group consisting of breast cancer, ovary cancer, colon cancer, liver cancer, central nervous system cancer, kidney cancer pancreas cancer and prostate cancer.

### Claim 16 (depends on 14)

The method according to claim 14 wherein the Erb-B2 positive cancer is Erb-B2 positive breast cancer.

### Claim 17 (depends on 13)

The method according to claim 13 wherein the cancer is selected from a cancer with deletion or mutation of the tumour suppressor p53 gene.
